Celgene reports detailed PFS data for Pomalyst triple combo in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III OPTIMISMM trial in 559 patients with relapsed or refractory multiple myeloma (MM) who received prior treatment with Revlimid lenalidomide showing that Pomalyst pomalidomide plus Velcade bortezomib and low-dose dexamethasone led to a median progression-free survival (PFS), the primary endpoint, of 11.2 months vs. 7.1 months for Velcade plus low-dose dexamethasone (HR=0.61, 95% CI: 0.49, 0.77, p<0.0001). Data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Celgene reported in February that the triple combination met the open-label, international trial's primary endpoint (see "Celgene's Pomalyst Plus Velcade and Dexamethasone Meets in Phase III for MM")...